| Line 143: | Line 143: | ||
*Using e‐cigarettes as a smoking cessation aid with standard behavioural support in stop‐smoking services in England is likely to be more cost‐effective than using nicotine replacement therapy in the same setting. | *Using e‐cigarettes as a smoking cessation aid with standard behavioural support in stop‐smoking services in England is likely to be more cost‐effective than using nicotine replacement therapy in the same setting. | ||
*[https://onlinelibrary.wiley.com/doi/epdf/10.1111/add.14829 PDF Version] | *[https://onlinelibrary.wiley.com/doi/epdf/10.1111/add.14829 PDF Version] | ||
===2014: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4238186/ E-cigarette versus nicotine inhaler: comparing the perceptions and experiences of inhaled nicotine devices]=== | |||
*Related Article: [https://www.cinj.org/patient-care/e-cigarettes-vs-nicotine-inhalers E-Cigarettes vs. Nicotine Inhalers] | |||
*“In conclusion, during this brief trial, the e-cigarette was found to be more acceptable, provided more satisfaction and rewards, and had higher perceived benefit than the nicotine inhaler. These findings may explain why the e-cigarette has become popular among smokers while the inhaler has not achieved the same favorability. Based on this difference, e-cigarettes could have the potential to become “tobacco cigarette substitutes,” owing to their high acceptance and perceived effectiveness. While toxicants have been identified in e-cigarettes, they are present at orders of magnitude lower than tobacco cigarettes. As such, e-cigarettes may hold value as a harm reduction strategy among those unwilling or unable to quit. However, given the large variation in the market with respect to brands, more data are needed to demonstrate their efficacy and safety, and to allow physicians to more appropriately inform their patients about these products.” | |||
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4238186/pdf/11606_2014_Article_2889.pdf PDF Version] | |||
<br> | <br> | ||
edits